Study Evaluates Budget Impact of Filgrastim and Similar Biologics for Treating Neutropenia

Jackie Syrop
April 07, 2017
Neutropenia, a common complication in patients administered myelosuppressive chemotherapy for nonmyeloid malignancies, is often treated with granulocyte colony-stimulating factors (G-CSFs). A budget impact study comparing home-administration of tbo-filgrastim, filgrastim-sndz, and filgrastim suggests that increasing tbo-filgrastim and filgrastim-sndz utilization for patients who self-administer the drugs may offer a more affordable option for US payers.

Tbo-filgrastim (Granix) and filgrastim-sndz (Zarxio) are, respectively, a follow-on biologic and a biosimilar version of the reference G-CSF filgrastim (Neupogen), with comparable efficacy and safety. Researchers Holly Trautman, PharmD, MS, of Aventine Consulting, Marblehead, MA, and colleagues created a budget impact model to estimate increasing utilization of home (patient)-administered tbo-filgrastim and filgrastim-sndz in patients with nonmyeloid malignancies treated with myelosuppressive chemotherapy from a US payer perspective. They estimated the changes in drug costs associated with projected increases in market share of tbo-filgrastim from 5% to 10% and filgrastim-sndz from 10% to 12%, for a 1-million-member health plan. The overall budget impact was calculated over a 1-year period, along with the difference in per-member, per-year (PMPY) cost between current and future scenarios. One-way sensitivity analyses were also conducted. 

It was assumed that 20% of patients receiving short-acting G-CSFs were self-administrating the medications at home. All products were decided upon through pharmacy benefits (Tier 3 formulary status; patient co-pay of $54/prescription). The model assumed syringe replacement rates of 1% for tbo-filgrastim and 5% for filgrastim and filgrastim-sndz because of differences in stability.

The effective annual plan per-patient drug cost totaled between $17,249 and $27,657, depending on dose and presentation, for tbo-filgrastim; between $17,043 and $27,332 for filgrastim-sndz; and between $18,034 and $32,212 for filgrastim. The estimated overall annual plan cost associated with short-acting G-CSFs was $55,920,046 (PMPY, $55.92) in the current scenario and $55,346,277 (PMPY, $55.34) in the future scenario. Estimated cost savings totaled $573,769 (PMPY, $0.58). The authors said the model was most sensitive to changes in the overall proportion of patients self-administering G-CSFs at home and to the wholesale acquisition cost for filgrastim.

Based on their analysis, the authors concluded that the effective annual plan per-patient drug cost for tbo-filgrastim and filgrastim-sndz was 14% to 15% lower than for filgrastim. “Estimated annual US health plan cost savings were in excess of $0.5 million overall, or $0.50 PMPY following small shifts in market shares,” they noted.

The authors presented their findings at the annual meeting of the Academy of Managed Care Pharmacy in Denver, Colorado, March 27-30, 2017.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.